In selected patients, cetuximab could be managed as an “immunotherapeutic drug” and association with NK-activating cytokines (IFNs, IL-2) [48] could also gain relevance in the attempt to activate ADCC against antibody-coated cancer cells. The gene discussed is IL2; the disease is cancer.